How Permanente Medicine is helping unlock the promise of biosimilars
Maisha Draves, MD, MPH, explains the potential of biosimilars in health care to expand access, improve affordability, and create better outcomes.
Dr. Awsare: Biosimilars in an integrated model help lower drug costs
Sameer Awsare, MD, tells Pink Sheet that Kaiser Permanente’s unique integrated structure helps it succeed in adopting biosimilars, resulting in lower drug costs for patients without sacrificing safety and efficacy.
Sameer Awsare, MD, discusses Permanente perspective on biosimilars
Sameer Awsare, MD, associate executive director for The Permanente Medical Group, shared in Biosimilars Development how Kaiser Permanente is a leader in the use of biosimilars.
Sameer Awsare, MD, highlights Kaiser Permanente model in case for biosimilars market
Physician leader Sameer Awsare, MD, FACP, co-writes an article in Health Affairs encouraging competition in the biosimilar drugs market to help curb rising health care costs.
Sameer Awsare, MD, focuses on Kaiser Permanente’s innovative approach to biosimilars at GRx+Biosims
Presenting at this week’s GRx+Biosims meeting in North Bethesda, Maryland, Sameer Awsare, MD, associate executive director of The Permanente Medical Group, elaborated on how Kaiser Permanente leverages its integrated care model to drive collaboration in advancing the move to biosimilars.
Sameer Awsare, MD, breaks down the basics of biosimilars
During a public briefing at the Alliance for Health Policy, Sameer Awsare, MD, of The Permanente Medical Group, joined other health care leaders to explain the mechanisms of biosimilar drugs.